Bladder Cancer

>

Latest News

Stable Health, Function in BCG-Unresponsive NMIBC With N-803 Plus BCG
Stable Health, Function in BCG-Unresponsive NMIBC With N-803 Plus BCG

February 6th 2024

Available data on patient-reported outcomes and positive interim results from QUILT 3.032 support N-803 for patients with Bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer.

Tailoring Treatment for High-Risk Bladder Cancer: Beyond BCG
Tailoring Treatment for High-Risk Bladder Cancer: Beyond BCG

February 2nd 2024

Enfortumab Vedotin/Pembrolizumab Outperforms Chemotherapy in mUC
Enfortumab Vedotin/Pembrolizumab Outperforms Chemotherapy in mUC

January 30th 2024

Genitourinary Cancers Symposium Roundup: A Comprehensive Overview
Genitourinary Cancers Symposium Roundup: A Comprehensive Overview

January 29th 2024

Adjuvant Pembrolizumab Shows Clinically Significant DFS Benefit in Urothelial Carcinoma
Adjuvant Pembrolizumab Shows Clinically Significant DFS Benefit in Urothelial Carcinoma

January 27th 2024

Video Series
Video Interviews

More News